ArticleClinical and experimental immunology2007
Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells.
Article in Clinical and experimental immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 94 citations in OpenAlex.
- Trial
- Antibiotics promote susceptibility tobioRxiv : the preprint server for biology · 2026Article
- Identification of diagnostic genes and drug prediction of allergic asthma by integrated bioinformatics analysis, machine learning, and molecular docking.The World Allergy Organization journal · 2025Article
- "Pleiotropic" Effects of Antibiotics: New Modulators in Human Diseases.Antibiotics (Basel, Switzerland) · 2024Review
- The Features and Treatment Effects on Keratoepitheliopathy for Meibomitis-Related Keratoconjunctivitis.Diagnostics (Basel, Switzerland) · 2024Article
- Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2.MedComm · 2023Review
- Explanatory predictive model for COVID-19 severity risk employing machine learning, shapley addition, and LIME.Scientific reports · 2023Article
- Clinical Trials Targeting Secondary Damage after Traumatic Spinal Cord Injury.International journal of molecular sciences · 2023Review
- Systemic and functional effects of continuous azithromycin treatment in patients with severe chronic obstructive pulmonary disease and frequent exacerbations.Frontiers in medicine · 2023Article
- Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection againstVirulence · 2022Article
- Current Status of the Spectrum and Therapeutics ofCancers · 2022Review
- The immunomodulatory effects of macrolide antibiotics in respiratory disease.Pulmonary pharmacology & therapeutics · 2021Review
- Upregulation of FOXP3 is associated with severity of hypoxia and poor outcomes in COVID-19 patients.Virology · 2021Article
- Article
- Azithromycin in viral infections.Reviews in medical virology · 2021Review
- Anti-MAP Triple Therapy Supports Immunomodulatory Therapeutic Response in Crohn's Disease through Downregulation of NF-κB Activation in the Absence of MAP Detection.Biomedicines · 2020Article
- Drug repurposing and cytokine management in response to COVID-19: A review.International immunopharmacology · 2020Review
- Possible mechanisms of action of clarithromycin and its clinical application as a repurposing drug for treating multiple myeloma.Ecancermedicalscience · 2020Review
- Bitter Taste Receptors (TAS2Rs) in Human Lung Macrophages: Receptor Expression and Inhibitory Effects of TAS2R Agonists.Frontiers in physiology · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Summary The macrolide antibiotics are now well known to have anti-inflammatory effects. Because dendritic cells (DCs) orchestrate immune responses, we examined the in vitro effects of clarithromycin (CAM), azithromycin (AZM) and midecamycin (MDM) on the expression of co-stimulatory molecules and production of cytokines [interleukin (IL)-10, IL-6, interferon (IFN)-gamma, IL-12p40, tumour necrosis factor (TNF)-alpha] of murine bone marrow-derived DCs by lipopolysaccharide (LPS) stimulation. A 15-membered macrolide, AZM, and a 14-membered macrolide, CAM, significantly enhanced the intensity of a co-stimulatory molecule, CD80, on DCs but not CD86 and CD40. AZM significantly increased the production of IL-10 and CAM significantly inhibited the production of IL-6 by DCs. However, a 16-membered macrolide, MDM, did not have any significant effect on these surface markers and cytokine productions. Moreover, AZM increased IL-10 and CAM decreased IL-2 productions significantly, when naive T cells derived from spleen were co-cultured with DCs treated in advance with LPS and these macrolides. These findings suggest that 14-membered and 15-membered, but not 16-membered macrolides play as anti-inflammatory agents, at least in part, through modulating the functions of DCs. However, each macrolide affects them in different ways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.